MidAmerica Cancer Center

American Oncology Partners

Kansas City, MO

Sorting 2 by

Accepting patients

MagnetisMM-32

Phase 3 Clinical Trial Comparing the Safety and Effectiveness of Elranatamab Versus Commonly Used Combination Regimens in Participants with Relapsed/Refractory Multiple Myeloma
  • Bispecific Antibody
  • BCMA
  • Randomization
  • Phase 3

Accepting patients

MajesTEC-7

A Study to Compare Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) in Participants With Newly Diagnosed Multiple Myeloma (MajesTEC-7)
  • Bispecific Antibody
  • BCMA
  • Randomization
  • Phase 3
  • Has results